We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site
Product News

Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site

Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site
Product News

Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellceutix Corporation reports that it has submitted for review the "Investigator's Brochure and Clinical Protocol" sections of its Investigational New Drug (IND) application for Kevetrin™, Cellceutix's drug in development as a treatment for cancers, to the world-renowned hospital in which it expects to host its Phase I clinical trials.

Upon review by the cancer center, Cellceutix will add the documents to the IND for submission to the FDA.

Leo Ehrlich, CEO of Cellceutix, stated, "I would like to congratulate the Cellceutix team including our many consultants, shareholders, and vendors on this important event. Yes, many thought it was impossible to accomplish what we have achieved.

Not only have we have created a new chemical class and breakthrough in medicine; we completed this at amazing speed, about three years, and expect shortly to file our IND. We are working diligently to see Cellceutix flourish and believe the best is yet to come."

Advertisement